SEARCHSYSTEMATIC_REVIEWoncology, infectious disease

systematic_review·oncology, infectious disease, preclinical research, biomedical research, systematic review·PMC10867388

Emerging strategies for combating Fusobacterium nucleatum in colorectal cancer treatment: Systematic review, improvements and future challenges

Exploration · 6 authors, 4 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

The review finds various materials show excellent antimicrobial performance in these preclinical settings, offering potential pathways beyond traditional antibiotics.

Full summary

394 CHARS

The review finds various materials show excellent antimicrobial performance in these preclinical settings, offering potential pathways beyond traditional antibiotics. However, significant limitations are noted, including unknown in vivo bioavailability, potential host cell toxicity, drug resistance concerns, short half-lives for antimicrobial peptides, and immune clearance of bacteriophages.

STUDY TYPE

systematic_review

SPECIALTY

oncology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10867388

Emerging strategies for combating Fusobacterium nucleatum in colorectal cancer treatment: Systematic review, improvements and future challenges

Exploration

READ THE FULL PAPER

ABSTRACT

Abstract Colorectal cancer (CRC) is generally characterized by a high prevalence of Fusobacterium nucleatum ( F. nucleatum ), a spindle‐shaped, Gram‐negative anaerobe pathogen derived from the oral cavity. This tumor‐resident microorganism has been closely correlated with the occurrence, progression, chemoresistance and immunosuppressive microenvironment of CRC. Furthermore, F. nucleatum can specifically colonize CRC tissues through adhesion on its surface, forming biofilms that are highly resistant to commonly used antibiotics. Accordingly, it is crucial to develop efficacious non‐antibiotic approaches to eradicate F. nucleatum and its biofilms for CRC treatment. In recent years, various antimicrobial strategies, such as natural extracts, inorganic chemicals, organic chemicals, polymers, inorganic‐organic hybrid materials, bacteriophages, probiotics, and vaccines, have been proposed to combat F. nucleatum and F. nucleatum biofilms. This review summarizes the latest advancements in anti‐ F. nucleatum research, elucidates the antimicrobial mechanisms employed by these systems, and discusses the benefits and drawbacks of each antimicrobial technology. Additionally, this review also provides an outlook on the antimicrobial specificity, potential clinical implications, challenges, and future improvements of these antimicrobial strategies in the treatment of CRC. Keywords: antibacterial, anti‐biofilm, colorectal cancer, drug resistance, Fusobacterium nucleatum

CITATION EXPORT

Hongyu Liu, Yunjian Yu, Alideertu Dong et al.. Emerging strategies for combating Fusobacterium nucleatum in colorectal cancer treatment: Systematic review, improvements and future challenges. Exploration. (2023). https://doi.org/10.1002/EXP.20230092

AUTHORS

6 · 4 CENTRES

Hongyu Liu, Yunjian Yu, Alideertu Dong, Mahmoud Elsabahy, Ying‐Wei Yang, Hui Gao

1 State Key Laboratory of Separation Membranes and Membrane Processes, School of Materials Science and Engineering, Tiangong University, Tianjin, P. R. China
2 College of Chemistry and Chemical Engineering, Inner Mongolia University, Hohhot, P. R. China
3 Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt
4 International Joint Research Laboratory of Nano‐Micro Architecture Chemistry, College of Chemistry, Jilin University, Changchun, P. R. China